Key result
Concomitant administration of PRV and OPV was noninferior to staggered administration for achieving poliovirus seroprotection and antirotavirus IgA seroresponse.
Why the study?
Does concomitant administration of PRV and OPV maintain noninferior immunogenicity compared to staggered administration in healthy infants?
RCT (n=735)
Open-label
randomized
Yes
Does concomitant administration of PRV and OPV maintain noninferior immunogenicity compared to staggered administration in healthy infants?
Coadministration of PRV and OPV does not interfere with poliovirus immune responses and maintains high rotavirus seroresponse rates, supporting their concomitant use in vaccination schedules.
Answers are grounded in this paper and cite their sources.
Supports coadministration of PRV and OPV in infant schedules; extends evidence for integrated vaccination programs.
OBJECTIVES: The live oral pentavalent rotavirus vaccine (PRV) is well tolerated and highly efficacious against rotavirus gastroenteritis. This open-label, multicenter study evaluated the immunogenicity and safety of coadministering oral poliovirus vaccine (OPV) with PRV. METHODS: From 2005 to 2006, healthy 6- to 12-week-old Latin American infants were randomized to PRV and OPV concomitantly or PRV 2-4 weeks before OPV. Three doses of each vaccine were administered 8-10 weeks apart. Subjects did not receive OPV at birth. Routine licensed pediatric vaccines were allowed. Antibody responses to PRV and OPV were evaluated 42 days after the last dose of each vaccine. Adverse events were recorded for 14 days after each study visit. RESULTS: In the concomitant-use group (n = 372), more than 98% of subjects achieved serum-neutralizing antibody titer > or = 1:8 against poliovirus types 1, 2, and 3. The poliovirus seroprotection rate in the concomitant-use group was statistically noninferior to the staggered-use group (n = 363). The immunoglobulin A (IgA) antirotavirus geometric mean titer was 46% lower in the concomitant-use group than in the staggered-use group. However, concomitant use elicited a > or = 3-fold increase (from predose 1 to postdose 3) in serum antirotavirus IgA in 93% of subjects and achieved the definition of noninferiority. Both regimens were similarly well tolerated. CONCLUSIONS: PRV did not interfere with immune responses to OPV. Although coadministration with OPV reduced serum antirotavirus IgA geometric mean titer, seroresponse rates were high and consistent with those observed in previous studies showing high vaccine efficacy. These results support including PRV in vaccination schedules involving OPV.
No takes yet. Share an insight, caveat, or question.
Ciarlet et al. (2008) conducted an RCT in Healthy infants (n=735). Concomitant oral pentavalent rotavirus vaccine (PRV) and oral poliovirus vaccine (OPV) vs. PRV 2-4 weeks before OPV (staggered use) was evaluated on Serum-neutralizing antibody titer ≥ 1:8 against poliovirus types 1, 2, and 3. Concomitant administration of PRV and OPV was noninferior to staggered administration for achieving poliovirus seroprotection and antirotavirus IgA seroresponse.
Synapse has enriched 10 related papers. Consider them for comparative context: